

PRESS RELEASE**AC Immune signs collaboration agreement with Nestlé Institute of Health Sciences to develop Alzheimer's disease diagnostic**

- **Development of minimally invasive Tau diagnostic assay for Alzheimer's disease**
- **Potential to identify Alzheimer's patients at very early and potentially pre-symptomatic stage of the disease**
- **Neurodegenerative expertise endorsed by fourth Tau collaboration**

Lausanne, Switzerland, - September 23, 2015 - AC Immune SA today announced that it has entered into a research collaboration agreement with the Nestlé Institute of Health Sciences SA (NIHS), a fundamental research institute of the global nutrition, health and wellness company Nestlé, to develop a novel, minimally invasive Tau diagnostic assay for the early diagnosis of Alzheimer's disease. Under the terms of the agreement AC Immune will provide its world leading expertise in the biology and pathology of Tau as well as committing its laboratory capabilities to support the collaborative research program. NIHS will apply its proprietary multiplexed antibody technology platform to the research program with the goal of identifying and validating a highly sensitive diagnostic assay for the detection of Tau in human cerebrospinal fluid (CSF) and blood plasma. Financial terms were not disclosed.

Prof. Andrea Pfeifer, CEO of AC Immune said: "We are very pleased about this research collaboration with the NIHS which marks our fourth partnership involving the Tau protein, endorsing our capability to develop both diagnostics and therapeutics for neurodegenerative diseases." She continued "The development of a minimally invasive diagnostic test to identify patients at very early stages is considered as one of the most pressing needs in Alzheimer's disease. Early diagnosis of this critical global health problem is equally needed for the development of pharmaceutical as well as nutritional approaches."

Prof. Ed Baetge, Head of NIHS, explains: "Our overarching goal is to develop nutritional approaches and technologies that help people maintain or re-establish their cognitive vigor. We share the conviction that early diagnosis is critical if we were to create pharmaceutical as well as targeted nutritional approaches for Alzheimer's disease. This collaboration agreement opens up exciting new possibilities in the quest to better understand and combat this debilitating disease".

The formation of Tau tangles, along with Abeta plaques, in the human brain are recognized as the two major hallmarks of Alzheimer's disease pathology. It is now well established that Tau correlates well with cognitive decline and disease progression. Therefore Tau may develop into a suitable companion biomarker for early diagnosis of

the disease. Such a diagnostic assay will be critical for the development of an Alzheimer's treatment and in the longer term may offer the opportunity for looking into disease prevention. Early diagnosis is an important first step in a more holistic approach of managing Alzheimer's and other neurodegenerative diseases using therapeutics and nutrition.

About NIHS proprietary multiplexed ultrasensitive tri-plex antibody technology

This is a patented diagnostic antibody based platform capable of measuring soluble proteins with high sensitivity and specificity to make measurements of target proteins which are not possible with other technologies. This antibody technology was developed by Prometheus Laboratories Inc., a Nestle Health Science company. NIHS has applied it in Brain Health research, specifically in Alzheimer's. The assay uses an antibody microarray-based platform that measures the expression and activation of target proteins in tissues, blood and other fluids.

About Alzheimer's disease

It is becoming increasingly clear that Alzheimer's disease (AD) develops because of a complex series of events that take place in the brain over a long period of time. Two proteins - Tau and beta-amyloid (A β) - are recognized as major hallmarks of neurodegeneration: tangles and other abnormal forms of Tau protein accumulate inside the brain cells and spread between cells, while plaques and oligomers formed by beta-amyloid occur outside the brain cells of people with Alzheimer's disease.

AD is one of the biggest burdens of society with a dramatic and growing worldwide incidence rate of one new case every three seconds, or 9.9 million new cases of dementia each year. Since the incidence and prevalence of AD increase with age, the number of patients will grow significantly as society gets older. Worldwide in 2015 there are 46.8 million people living with dementia and by 2050 it is expected that global patient numbers will triple to 131.5 million. It is estimated that the annual societal and economic cost of dementia has risen from US\$ 604 billion in 2010 to US\$ 818 billion in 2015. In the US AD is now the 6th leading cause of death across all ages and is the fifth leading cause of death for those aged 65 and older.

About AC Immune

AC Immune is a leading Swiss-based biopharmaceutical company focused on neurodegenerative diseases with three products in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines to address large markets across a broad spectrum of neurodegenerative indications. Alzheimer's disease (AD) is the largest indication addressed by its products but the company's innovative, highly differentiated and disease-modifying therapies are designed to shift the paradigm in the treatment of other neurodegenerative diseases such as Parkinson's, Down syndrome,

and Glaucoma. The Company has a large, diversified and promising pipeline featuring seven therapeutic and three diagnostic products. The most advanced of these is crenezumab, an anti-Abeta antibody that is licensed to Genentech entering phase III. Crenezumab was chosen by the US National Institute of Health for use in the first-ever AD prevention trial. The company has partnered three programs targeting Tau: ACI-35 with Janssen (therapeutic vaccine, phase Ib), Tau PET tracers with Piramal (Alzheimer's diagnostic agent) and Tau-antibodies with Genentech (preclinical). The anti-Abeta vaccine ACI-24 phase I/IIa trial is run in house. Since its foundation in 2003, AC Immune has raised 84 million Swiss francs from private investors.

For further information, please contact:

<p>AC Immune Prof. Andrea Pfeifer Chief Executive Officer Phone: +41-21-693 91 21 E-mail: andrea.pfeifer@acimmune.com</p>	<p>Eva Schier Corporate Communications Manager Phone: +41-21-693 91 34 E-mail: eva.schier@acimmune.com</p>
<p>Nick Miles Senior Consultant Cabinet Privé de Conseils s.a. Mobile : +41 79 678 76 26 E-mail : miles@cpc-pr.com</p>	<p>In the US Ted Agne The Communications Strategy Group Inc. Phone: +1 781 631 3117 E-mail: edagne@comstratgroup.com</p>